The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells

BACKGROUND: Histone deacetylase (HDAC) inhibitors are a class of agents that have potent antitumor activity with a reported ability to upregulate MHC and costimulatory molecule expression. We hypothesized that epigenetic pharmacological immunomodulation could sensitize tumors to immune mediated cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Lisiero, Dominique N, Soto, Horacio, Everson, Richard G, Liau, Linda M, Prins, Robert M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105687/
https://www.ncbi.nlm.nih.gov/pubmed/25054063
http://dx.doi.org/10.1186/2051-1426-2-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105687/
https://www.ncbi.nlm.nih.gov/pubmed/25054063
http://dx.doi.org/10.1186/2051-1426-2-8

Ejemplares similares